{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T14:54:23Z","timestamp":1791384863192,"version":"4.3.3"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,5,6]],"date-time":"2020-05-06T00:00:00Z","timestamp":1588723200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2020,5,6]],"date-time":"2020-05-06T00:00:00Z","timestamp":1588723200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"The EOD Group, KCCR","award":["NA"],"award-info":[{"award-number":["NA"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Infect Dis"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Praziquantel (PZQ) is the standard treatment for Schistosomiasis in sub-Saharan Africa. However, there is evidence suggesting praziquantel treatment failure in Schistosome infections with associated potential renal impairment. The objective of this study was to determine the effect of three monthly doses of 60\u2009mg\/kg\/day PZQ on schistosome egg count, liver and renal function during the treatment of urinary schistosomiasis in Ghana.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      A nested case-control study was designed from a cohort screened for schistosomiasis; 28 schistosomiasis positive cases by microscopy matched with 53 healthy controls by age and gender. The study population was urban dwellers from the Asokwa sub-metropolitan area, Kumasi in Ghana. Participants were within the age range of 6 to 30\u2009years. We assessed\n                      <jats:italic>Schistosoma haematobium<\/jats:italic>\n                      egg counts in urine and its associated impact on liver and renal function at baseline, treatment and post-treatment phases using serum.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Of the 28 cases and 53 controls, 78.6% and 81.1% were males respectively. Globulin levels before treatment was higher in cases [36.7 (32.8, 40.1) vrs 30.5 (22.4, 33.8),\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.005] at pre-treatment but not at post-treatment [35.8 (31.2, 39.1) vrs 37.4 (29.7, 43.0),\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.767]. Estimated cure rate was 42.9, 46.4 and 96.4% after first, second and third dose respectively. Schistosome egg counts dropped significantly (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.001) from before second dose to post-treatment. Similarly, levels of alanine aminotransferase (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.001), aspartate aminotransferase (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.028) and gamma glutamyl transferase (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.001) significantly declined towards post-treatment. Estimated glomerular filtration rate significantly improved from before second dose to post-treatment using both the Chronic Kidney Disease Epidemiology Program (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.001) and 4-variable Modification of Diet in Renal Disease (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.002) equations.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>\n                      Treatment of urinary\n                      <jats:italic>Schistosoma hematobium<\/jats:italic>\n                      infections with a repeated high monthly dose of 60\u2009mg\/kg of praziquantel for 3\u2009months is safe and effective.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12879-020-05053-z","type":"journal-article","created":{"date-parts":[[2020,5,6]],"date-time":"2020-05-06T08:04:25Z","timestamp":1588752265000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Three monthly doses of 60\u2009mg\/kg praziquantel for Schistosoma haematobium infection is a safe and effective treatment regimen"],"prefix":"10.1186","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0750-4311","authenticated-orcid":false,"given":"Samuel Nkansah","family":"Darko","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henry","family":"Hanson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sampson","family":"Twumasi-Ankrah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra","family":"Baffour-Awuah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Priscilla","family":"Adjei-Kusi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Denis","family":"Yar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ellis","family":"Owusu-Dabo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,5,6]]},"reference":[{"issue":"13","key":"5053_CR1","doi-asserted-by":"publisher","first-page":"1825","DOI":"10.1017\/S0031182009000493","volume":"136","author":"M Doenhoff","year":"2009","unstructured":"Doenhoff M, Hagan P, Cioli D, Southgate V, Pica-Mattoccia L, Botros S, Coles G, Tchuem Tchuent\u00e9 L, Mbaye A, Engels D. Praziquantel: its use in control of schistosomiasis in sub-Saharan Africa and current research needs. Parasitology. 2009;136(13):1825\u201335.","journal-title":"Parasitology"},{"issue":"4","key":"5053_CR2","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1016\/j.ijpara.2003.12.003","volume":"34","author":"L Pica-Mattoccia","year":"2004","unstructured":"Pica-Mattoccia L, Cioli D. Sex-and stage-related sensitivity of Schistosoma mansoni to in vivo and in vitro praziquantel treatment. Int J Parasitol. 2004;34(4):527\u201333.","journal-title":"Int J Parasitol"},{"key":"5053_CR3","volume-title":"Praziquantel for the treatment of schistosomiasis: its use for control in areas with endemic disease and prospects for drug resistance","author":"MJ Doenhoff","year":"2006","unstructured":"Doenhoff MJ, Pica-Mattoccia L. Praziquantel for the treatment of schistosomiasis: its use for control in areas with endemic disease and prospects for drug resistance; 2006."},{"issue":"6","key":"5053_CR4","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1016\/j.ijpara.2006.02.002","volume":"36","author":"MC Jeziorski","year":"2006","unstructured":"Jeziorski MC, Greenberg RM. Voltage-gated calcium channel subunits from platyhelminths: potential role in praziquantel action. Int J Parasitol. 2006;36(6):625\u201332.","journal-title":"Int J Parasitol"},{"issue":"9","key":"5053_CR5","doi-asserted-by":"publisher","first-page":"1779","DOI":"10.1016\/0006-2952(94)90464-2","volume":"48","author":"CM Masimirembwa","year":"1994","unstructured":"Masimirembwa CM, Hasler JA. Characterisation of praziquantel metabolism by rat liver microsomes using cytochrome P450 inhibitors. Biochem Pharmacol. 1994;48(9):1779\u201383.","journal-title":"Biochem Pharmacol"},{"issue":"3","key":"5053_CR6","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1093\/infdis\/169.3.689","volume":"169","author":"WD Dachman","year":"1994","unstructured":"Dachman WD, Adubofour KO, Bikin DS, Johnson CH, Mullin PD, Winograd M. Cimetidine-induced rise in praziquantel levels in a patient with neurocysticercosis being treated with anticonvulsants. J Infect Dis. 1994;169(3):689\u201391.","journal-title":"J Infect Dis"},{"issue":"5","key":"5053_CR7","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1067\/mcp.2002.129319","volume":"72","author":"W Ridtitid","year":"2002","unstructured":"Ridtitid W, Wongnawa M, Mahatthanatrakul W, Punyo J, Sunbhanich M. Rifampin markedly decreases plasma concentrations of praziquantel in healthy volunteers. Clin Pharmacol Ther. 2002;72(5):505\u201313.","journal-title":"Clin Pharmacol Ther"},{"key":"5053_CR8","unstructured":"Zimmerman HJ. Hepatotoxicity: the adverse effects of drugs and other chemicals on the liver. Philadelphia: Lippincott Williams & Wilkins; 1999."},{"issue":"4","key":"5053_CR9","first-page":"495","volume":"14","author":"M Chen","year":"1983","unstructured":"Chen M, Fu S, Hua X, Wu H. A retrospective survey on side effects of praziquantel among 25,693 cases of schistosomiasis japonica. Southeast Asian J Trop Med Public Health. 1983;14(4):495\u2013500.","journal-title":"Southeast Asian J Trop Med Public Health"},{"issue":"5","key":"5053_CR10","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1016\/S0035-9203(02)90405-0","volume":"96","author":"MJ Doenhoff","year":"2002","unstructured":"Doenhoff MJ, Kusel JR, Coles GC, Cioli D. Resistance of Schistosoma mansoni to praziquantel: is there a problem? Trans R Soc Trop Med Hyg. 2002;96(5):465\u20139.","journal-title":"Trans R Soc Trop Med Hyg"},{"key":"5053_CR11","volume-title":"2010 Population and housing census summary of final results","author":"GSS","year":"2012","unstructured":"GSS. 2010 Population and housing census summary of final results. Ghana: Ghana Statistical Service; 2012."},{"key":"5053_CR12","unstructured":"MSD. Annual Report (Meteorological Statistical Department, Kumasi). Ghana: Ghana Meteorological Agency; 2011."},{"key":"5053_CR13","doi-asserted-by":"crossref","unstructured":"Cheesbrough M. District laboratory practice in tropical countries. New York: Cambridge University Press; 2006.","DOI":"10.1017\/CBO9780511543470"},{"issue":"6","key":"5053_CR14","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.2215\/CJN.06870909","volume":"5","author":"WM Michels","year":"2010","unstructured":"Michels WM, Grootendorst DC, Verduijn M, Elliott EG, Dekker FW, Krediet RT. Performance of the Cockcroft-Gault, MDRD, and new CKD-EPI formulas in relation to GFR, age, and body size. Clin J Am Soc Nephrol. 2010;5(6):1003\u20139.","journal-title":"Clin J Am Soc Nephrol"},{"issue":"9","key":"5053_CR15","doi-asserted-by":"publisher","first-page":"1205","DOI":"10.1086\/651682","volume":"50","author":"J Keiser","year":"2010","unstructured":"Keiser J, N'guessan NA, Adoubryn KD, Silu\u00e9 KD, Vounatsou P, Hatz C, Utzinger J, N'goran EK. Efficacy and safety of mefloquine, artesunate, mefloquine-artesunate, and praziquantel against Schistosoma haematobium: randomized, exploratory open-label trial. Clin Infect Dis. 2010;50(9):1205\u201313.","journal-title":"Clin Infect Dis"},{"issue":"5","key":"5053_CR16","first-page":"614","volume":"15","author":"A Guidi","year":"2010","unstructured":"Guidi A, Andolina C, Makame Ame S, Albonico M, Cioli D, Juma Haji H. Praziquantel efficacy and long-term appraisal of schistosomiasis control in Pemba Island. Tropical Med Int Health. 2010;15(5):614\u20138.","journal-title":"Tropical Med Int Health"},{"issue":"10","key":"5053_CR17","doi-asserted-by":"publisher","first-page":"e6732","DOI":"10.1371\/journal.pone.0006732","volume":"4","author":"MS Sissoko","year":"2009","unstructured":"Sissoko MS, Dabo A, Traor\u00e9 H, Diallo M, Traor\u00e9 B, Konat\u00e9 D, Niar\u00e9 B, Diakit\u00e9 M, Kamat\u00e9 B, Traor\u00e9 A. Efficacy of artesunate+ sulfamethoxypyrazine\/pyrimethamine versus praziquantel in the treatment of Schistosoma haematobium in children. PLoS One. 2009;4(10):e6732.","journal-title":"PLoS One"},{"issue":"2","key":"5053_CR18","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1016\/j.actatropica.2012.08.008","volume":"128","author":"A Garba","year":"2013","unstructured":"Garba A, Lamine MS, Barkir\u00e9 N, Djibo A, Sofo B, Gouvras AN, Labbo R, Sebangou H, Webster JP, Fenwick A. Efficacy and safety of two closely spaced doses of praziquantel against Schistosoma haematobium and S. mansoni and re-infection patterns in school-aged children in Niger. Acta Trop. 2013;128(2):334\u201344.","journal-title":"Acta Trop"},{"issue":"2","key":"5053_CR19","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1016\/j.actatropica.2013.06.007","volume":"128","author":"L-AT Tchuent\u00e9","year":"2013","unstructured":"Tchuent\u00e9 L-AT, Momo SC, Stothard JR, Rollinson D. Efficacy of praziquantel and reinfection patterns in single and mixed infection foci for intestinal and urogenital schistosomiasis in Cameroon. Acta Trop. 2013;128(2):275\u201383.","journal-title":"Acta Trop"},{"issue":"2","key":"5053_CR20","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1093\/clinids\/20.2.309","volume":"20","author":"BL Herwaldt","year":"1995","unstructured":"Herwaldt BL, Tao L f, van Pelt W, Tsang VC, Bruce JI. Persistence of Schistosoma haematobium infection despite multiple courses of therapy with praziquantel. Clin Infect Dis. 1995;20(2):309\u201315.","journal-title":"Clin Infect Dis"},{"issue":"2","key":"5053_CR21","doi-asserted-by":"publisher","first-page":"342","DOI":"10.4269\/ajtmh.2006.74.342","volume":"74","author":"D Alonso","year":"2006","unstructured":"Alonso D, Mu\u00f1oz J, Gasc\u00f3n J, Valls ME, Corachan M. Failure of standard treatment with praziquantel in two returned travelers with Schistosoma haematobium infection. Am J Trop Med Hygiene. 2006;74(2):342\u20134.","journal-title":"Am J Trop Med Hygiene"},{"issue":"8","key":"5053_CR22","doi-asserted-by":"publisher","first-page":"2481","DOI":"10.1016\/j.bmcl.2010.03.001","volume":"20","author":"Y Dong","year":"2010","unstructured":"Dong Y, Chollet J, Vargas M, Mansour NR, Bickle Q, Alnouti Y, Huang J, Keiser J, Vennerstrom JL. Praziquantel analogs with activity against juvenile Schistosoma mansoni. Bioorg Med Chem Lett. 2010;20(8):2481\u20134.","journal-title":"Bioorg Med Chem Lett"},{"key":"5053_CR23","doi-asserted-by":"publisher","first-page":"d2651","DOI":"10.1136\/bmj.d2651","volume":"342","author":"DJ Gray","year":"2011","unstructured":"Gray DJ, Ross AG, Li Y-S, McManus DP. Diagnosis and management of schistosomiasis. Bmj. 2011;342:d2651.","journal-title":"Bmj"},{"issue":"5","key":"5053_CR24","doi-asserted-by":"publisher","first-page":"1871","DOI":"10.1007\/s00436-012-3151-z","volume":"111","author":"W Wang","year":"2012","unstructured":"Wang W, Wang L, Liang Y-S. Susceptibility or resistance of praziquantel in human schistosomiasis: a review. Parasitol Res. 2012;111(5):1871\u20137.","journal-title":"Parasitol Res"},{"issue":"3","key":"5053_CR25","first-page":"877","volume":"23","author":"A El-Fakahany","year":"1993","unstructured":"El-Fakahany A, Abdalla K, El-Hady H, Se-A A, Afifi L. The effect of praziquantel treatment on the liver functions, worm burden, and granuloma size using two drug regimen in murine Schistosoma mansoni infection. J Egypt Soc Parasitol. 1993;23(3):877\u201386.","journal-title":"J Egypt Soc Parasitol"},{"issue":"1","key":"5053_CR26","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1111\/j.1574-695X.2009.00640.x","volume":"58","author":"SA Rahoud","year":"2010","unstructured":"Rahoud SA, Mergani A, Khamis AH, Saeed OK, Mohamed-Ali Q, Dessein AJ, Elwali NEM. Factors controlling the effect of praziquantel on liver fibrosis in Schistosoma mansoni-infected patients. FEMS Immunol Med Microbiol. 2010;58(1):106\u201312.","journal-title":"FEMS Immunol Med Microbiol"},{"issue":"5","key":"5053_CR27","doi-asserted-by":"publisher","first-page":"e02582","DOI":"10.1128\/AAC.02582-16","volume":"61","author":"N Vale","year":"2017","unstructured":"Vale N, Gouveia MJ, Rinaldi G, Brindley PJ, G\u00e4rtner F, da Costa JMC. Praziquantel for schistosomiasis: single-drug metabolism revisited, mode of action, and resistance. Antimicrob Agents Chemother. 2017;61(5):e02582\u201316.","journal-title":"Antimicrob Agents Chemother"}],"container-title":["BMC Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-020-05053-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12879-020-05053-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-020-05053-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,5]],"date-time":"2021-05-05T19:29:05Z","timestamp":1620242945000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcinfectdis.biomedcentral.com\/articles\/10.1186\/s12879-020-05053-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5,6]]},"references-count":27,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["5053"],"URL":"https:\/\/doi.org\/10.1186\/s12879-020-05053-z","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.2.19724\/v1","asserted-by":"object"},{"id-type":"doi","id":"10.21203\/rs.2.19724\/v2","asserted-by":"object"},{"id-type":"doi","id":"10.21203\/rs.2.19724\/v3","asserted-by":"object"}]},"ISSN":["1471-2334"],"issn-type":[{"value":"1471-2334","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,5,6]]},"assertion":[{"value":"9 December 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 April 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 May 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Ethical approval was obtained from the Committee for Human Research Publication and Ethics, School of Medical Sciences, Kwame Nkrumah University of Science and Technology, Ghana (CHRPE\/AP\/227\/17). All participants were required to sign an informed consent. For minors below 16\u2009years, a signed assent form from the participant and an informed consent from a parent or guardian were requirements for participation.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"323"}}